公开(公告)号：US20200102360A1

公开(公告)日：2020-04-02

申请号：US16714112

申请日：2019-12-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: C07K14/47 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200088726A1

公开(公告)日：2020-03-19

申请号：US16569691

申请日：2019-09-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andreas MORITZ ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER

IPC: G01N33/569 ,  C07K14/74 ,  A61K39/395 ,  A61K38/17

Abstract: The present invention relates to a method for high throughput screening for a TCR-binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids.

公开(公告)号：US20180164315A1

公开(公告)日：2018-06-14

申请号：US15835095

申请日：2017-12-07

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： LEONIE ALTEN ,  SEBASTIAN BUNK ,  DOMINIK MAURER ,  Claudia WAGNER

IPC: G01N33/574 ,  C07K16/28 ,  G01N33/58 ,  A61K39/395 ,  A61K35/17

Abstract: The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20250163124A1

公开(公告)日：2025-05-22

申请号：US19024104

申请日：2025-01-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Sebastian BUNK ,  Dominik MAURER ,  Jens FRITSCHE ,  Claudia WAGNER ,  Leonie ALTEN ,  Franziska HOFFGAARD ,  Mathias FERBER

IPC: C07K14/725 ,  A61K35/17 ,  C12N5/0783 ,  C12N15/09

Abstract: The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.

公开(公告)号：US20250154246A1

公开(公告)日：2025-05-15

申请号：US18916878

申请日：2024-10-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Claudia WAGNER ,  Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER

IPC: C07K16/26 ,  A61K40/11 ,  A61K40/32 ,  A61K40/42 ,  C07K14/725 ,  C07K14/81 ,  C07K16/28 ,  C07K16/38 ,  C12N5/0783 ,  C12N15/85

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20240052054A1

公开(公告)日：2024-02-15

申请号：US18483174

申请日：2023-10-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Meike HUTT ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER ,  Martin HOFMANN ,  Gabriele PSZOLLA ,  Sara YOUSEF ,  Claudia WAGNER ,  Frank SCHWOEBEL ,  Heiko SCHUSTER

IPC: C07K16/30 ,  C07K14/725 ,  A61P35/00

CPC classification number: C07K16/30 ,  C07K14/7051 ,  A61P35/00 ,  C07K2317/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/567 ,  C07K2317/92 ,  C07K2317/55 ,  C07K2317/565

Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20220211833A1

公开(公告)日：2022-07-07

申请号：US17692264

申请日：2022-03-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220184194A1

公开(公告)日：2022-06-16

申请号：US17681447

申请日：2022-02-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210388079A1

公开(公告)日：2021-12-16

申请号：US17397656

申请日：2021-08-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Claudia WAGNER ,  Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER

IPC: C07K16/26 ,  C07K14/725 ,  C07K14/81 ,  C07K16/28 ,  C07K16/38 ,  C12N15/85 ,  C12N5/0783

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20210322527A1

公开(公告)日：2021-10-21

申请号：US17327190

申请日：2021-05-21

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K14/74 ,  C07K14/47 ,  C07K16/18

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.